By Stephen Nakrosis 

Biogen Inc. on Thursday said its Tecfidera received approval from China's National Medical Products Administration for the treatment of relapsing multiple sclerosis.

The company said Tecfidera, or dimethyl fumarate, "was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs."

The company said the approval was based on data from "the global, pivotal Phase 3 DEFINE and CONFIRM studies, which enrolled more than 2,600 patients."

Biogen said Tecfidera was introduced in 2013 and has been used to treat more than 500,000 individuals with MS worldwide.


--Write to Stephen Nakrosis at


(END) Dow Jones Newswires

April 15, 2021 17:37 ET (21:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.